You are here

  • Home
  • Archive
  • Volume 70, Issue 8
  • Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study

Article info

Article menu
Download PDFPDF
Inflammatory bowel disease
Original research
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study

Authors

  1. Correspondence to Dr Nicolas Pierre, Laboratory of Translational Gastroenterology, GIGA-institute, Liege University, 4000 Liege, Belgium; nicolas.pierre{at}uliege.be
View Full Text

Citation

Pierre N, Baiwir D, Huynh-Thu VA GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif), et al
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study
Gut 2021;70:1450-1457.

Publication history

  • Received June 10, 2020
  • Revised September 30, 2020
  • Accepted October 2, 2020
  • First published October 26, 2020.
Online issue publication 
January 23, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.